Toffoli G - Search Results

1

Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy.

Bayda S, Hadla M, Palazzolo S, Kumar V, Caligiuri I, Ambrosi E, Pontoglio E, Agostini M, Tuccinardi T, Benedetti A, Riello P, Canzonieri V, Corona G, Toffoli G, Rizzolio F. Bayda S, et al. Among authors: toffoli g. J Control Release. 2017 Feb 28;248:144-152. doi: 10.1016/j.jconrel.2017.01.022. Epub 2017 Jan 14. J Control Release. 2017. PMID: 28093297 Free article.

2

Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.

Toffoli G, Corona G, Gigante M, Boiocchi M. Toffoli G, et al. Eur J Cancer. 1996 Aug;32A(9):1591-7. doi: 10.1016/0959-8049(96)00113-x. Eur J Cancer. 1996. PMID: 8911123

3

Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.

Toffoli G, Sorio R, Gigante M, Corona G, Galligioni E, Boiocchi M. Toffoli G, et al. Br J Cancer. 1997;75(5):715-21. doi: 10.1038/bjc.1997.127. Br J Cancer. 1997. PMID: 9043030 Free PMC article. Clinical Trial.

4

Pharmacology of chronic oral daily administration of idarubicin.

Toffoli G, Sorio R, Aita P, Crivellari D, Corona G, Rimondi G, Bearz A, Stocco F, Robieux I, Boiocchi M. Toffoli G, et al. Haematologica. 1997 Sep-Oct;82(5 Suppl):1-3. Haematologica. 1997. PMID: 9402745 Clinical Trial.

5

Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.

Toffoli G, Sorio R, Aita P, Crivellari D, Corona G, Bearz A, Robieux I, Colussi AM, Stocco F, Boiocchi M. Toffoli G, et al. Clin Cancer Res. 2000 Jun;6(6):2279-87. Clin Cancer Res. 2000. PMID: 10873078 Clinical Trial.

6

Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.

Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Toffoli G, et al. Int J Cancer. 2003 Jan 20;103(3):294-9. doi: 10.1002/ijc.10847. Int J Cancer. 2003. PMID: 12471611 Free article.

7

Pharmacogenetics of irinotecan.

Toffoli G, Cecchin E, Corona G, Boiocchi M. Toffoli G, et al. Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. doi: 10.2174/1568011033482477. Curr Med Chem Anticancer Agents. 2003. PMID: 12769780 Review.

8

Pharmacokinetic optimisation of treatment with oral etoposide.

Toffoli G, Corona G, Basso B, Boiocchi M. Toffoli G, et al. Clin Pharmacokinet. 2004;43(7):441-66. doi: 10.2165/00003088-200443070-00002. Clin Pharmacokinet. 2004. PMID: 15139794 Review.

9

Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.

Toffoli G, Sorio R, Basso B, Aita P, Corona G, Rupolo M, Boiocchi M. Toffoli G, et al. J Chemother. 2004 Apr;16(2):193-200. doi: 10.1179/joc.2004.16.2.193. J Chemother. 2004. PMID: 15216956

10

Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.

Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U, Vaccher E. Toffoli G, et al. Ann Oncol. 2004 Dec;15(12):1805-9. doi: 10.1093/annonc/mdh464. Ann Oncol. 2004. PMID: 15550586 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

345 results

Search Page